2024-04-11 10:25:50 ET
Summary
- Among their more prominent programs, Moderna is developing a vaccine-based treatment for solid tumors.
- Moderna's personalized neoantigen vaccine, mRNA-4157, has shown promising results in clinical trials for melanoma, and some preliminary activity in head and neck carcinoma.
- A neoantigen-based program could very well become a key pillar of MRNA's future, but this is just one piece of the investment puzzle.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Moderna: Considering The Cancer Vaccine Angle